Exelixis Inc

Exelixis Inc

EXEL - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$17.03B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Exelixis IncExelixis Inc20-35%9.90.1
$52.75

Target Price by Analysts

23.6% downsideExelixis Target Price DetailsTarget Price
$163.26

Current Fair Value

136.6% upside

Undervalued by 136.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$17.03 Billion
Enterprise Value$16.91 Billion
Earnings per Share$2.88
Beta0.42
Outstanding Shares246,756,000

Return

Return on Equity34.74%ROE
Return on Assets25.68%
Return on Invested Capital36.69%

Valuation & Multiples

P/E Ratio20P/E Ratio
PEG157.91PEG
Price to Sales9.86Price to Sales
Price to Book Ratio9.86Price to Book Ratio
Enterprise Value to Revenue8.91
Enterprise Value to EBIT21.61
Enterprise Value to Net Income26
Total Debt to Enterprise0.01
Debt to Equity0.09Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 3, 2026
EPS Estimate
$0.88
Consensus analyst estimate
Revenue Estimate
$646.95 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 9, 2027
EPS Estimate
$1.04
Consensus analyst estimate
Revenue Estimate
$659.70 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 4.93, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.

Put/Call Ratio4.9280▲ 410.96%
Total Calls201,400▼ 78.04%
Total Puts992,500▲ 32.23%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %73.14%▼ 31.07%
Total Invested$10.73B▼ 24.53%
Investors Holding645▼ 136.00%

About Exelixis Inc

1,077 employees
CEO: Michael Morrissey

Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company m...

Exelixis Insider Information FAQ

Stockcircle tracks 7 top investors with a current 13F position in Exelixis. Notable holders include Bridgewater Associates. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 3 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 7 open-market insider sales for Exelixis in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.